Skip to main
IRTC

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies (IRTC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

iRhythm Holdings Inc demonstrated a robust financial performance, highlighted by a gross margin of 71.1%, marking a 230 basis point increase year-over-year and surpassing market expectations. For 2025, the company maintains a revenue outlook of $870-$880 million, indicating a growth rate of 16-18% year-over-year, complemented by strong contributions from its Zio AT product line and positive trends in pricing and mix. Additionally, iRhythm anticipates annual EBITDA margin improvements of approximately 400 basis points, driven by factors such as increased ambulatory cardiac testing volume, international expansion, and enhanced operational efficiency, positioning the company for sustained profitability.

Bears say

iRhythm Holdings faces a bearish outlook primarily due to anticipated growth slowing to the low-teens, alongside insufficient improvements in profitability. Competitive pressures in the extended-wear cardiac monitoring market, coupled with potential challenges in new product launches like ZioAT, could hinder market traction and limit sales opportunities. Furthermore, rising risks such as negative developments in commercial reimbursements, poor sales execution, and possible equity offerings exacerbate uncertainties regarding the company's financial performance.

iRhythm Technologies (IRTC) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iRhythm Technologies (IRTC) Forecast

Analysts have given iRhythm Technologies (IRTC) a Buy based on their latest research and market trends.

According to 12 analysts, iRhythm Technologies (IRTC) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $208.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $208.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iRhythm Technologies (IRTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.